CTXR stock forecast also considers macroeconomic data. Lower interest rates historically boost small-cap biotech valuations by reducing financing costs, an environment that could favor CTXR in the near term. This biotech firm has caught the eye of Stifel analyst Alex Thompson, who sees the TransCon PTH drug as the main factor to bring in investors. He writes of Ascendis, “ASND’s TransCon PTH is the key focus of the stock… We remain confident in the prospects for approval in the US despite multiple delays… Hypoparathyroidism represents a multi-billion euro commercial opportunity on the backdrop of a growth hormone base business (Skytrofa) that can continue to grow via broader transition of the daily market to weekly and label expansion – even in the presence of major competitive threats. To that end, we model peak sales for TransCon PTH in Hypoparathyroidism of €3.0B based on conservative penetration assumptions and Skytrofa sales of €1.3B, above and in-line/lower than consensus estimates, respectively.” These comments back up Thompson’s Buy rating on the stock, and his price target, set at $200, implies an upside of 47% on the one-year horizon. (To watch Thompson’s track record, click here ) Analyst consensus for CTXR stock forecast remains in speculative territory, with most coverage emphasizing binary risks tied to trial outcomes. This is typical for biotech names without significant existing revenue streams.